Related Experiment Video

Updated: May 16, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.3K

Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations

Sowndharya M1, Ramesh Joga1, Kajal Gandhi1

  • 1Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research, India.

Pharmaceutical Patent Analyst
|May 15, 2025
PubMed
Abstract

Insights

Proteolysis Targeting Chimeras (PROTACs) offer a novel approach to targeted protein degradation for challenging diseases. Navigating their unique regulatory landscape is key for safe and effective clinical translation.

Area of Science:

  • Drug discovery and development
  • Molecular biology
  • Biotechnology

Background:

  • Proteolysis Targeting Chimeras (PROTACs) represent a significant advancement in targeted protein degradation.
  • PROTACs utilize the body's natural degradation pathways to eliminate pathogenic proteins, offering potential for previously untreatable diseases like cancer and neurodegenerative disorders.
  • The rapid development of PROTACs necessitates a clear understanding of their regulatory approval pathways.

Purpose of the Study:

  • To review recent patents, regulatory considerations, emerging concerns, and future perspectives of PROTACs in cancer management.
  • To highlight the unique challenges and opportunities in the regulatory landscape for PROTACs.
  • To emphasize the need for tailored guidelines and rigorous evaluation for PROTACs.

Main Methods:

  • Review of recent patents and regulatory documents.
  • Analysis of emerging concerns and future trends in PROTAC development.
  • Synthesis of expert opinions on regulatory pathways.

Main Results:

  • PROTACs present unique regulatory challenges due to their dual-functional nature, requiring a blend of small-molecule and biologic frameworks.
  • Specific guidelines for pharmacokinetic and pharmacodynamic profiles, preclinical evaluation, and clinical trial design are essential.
  • Collaboration among regulatory bodies, academia, and industry is crucial for establishing clear approval pathways.

Conclusions:

  • The regulatory journey for PROTACs requires tailored guidelines and rigorous evaluation to ensure safe and effective therapies.
  • Addressing off-target effects and immunogenic responses through robust preclinical and clinical studies is paramount.
  • Continued advancements in PROTAC technology must be integrated into future regulatory considerations to realize their full therapeutic potential.
Keywords:
CancerPROTACsemerging strategiesprogressrecent patentsregulatory considerationstargeted protein degradationubiquitin-proteasome system

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Regulated Protein Degradation02:58

Regulated Protein Degradation

2.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.7K